Seagen Inc. Files Form 8-K Following Pfizer Acquisition

Seagen Inc. has announced that it has entered into an Agreement and Plan of Merger with Pfizer Inc. and Aris Merger Sub, Inc., with the Company set to be acquired by Pfizer in a deal that remains subject to regulatory approvals and other closing conditions. The merger agreement was first disclosed on March 12, 2023, and Seagen Inc. has since filed a Notification and Report Form with the Federal Trade Commission and Department of Justice under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The parties have agreed to withdraw the initial filing and refile it, with the statutory waiting period under the HSR Act set to expire on July 14, 2023.

Key Takeaways:

• Seagen Inc. has filed Form 8-K with the U.S. Securities and Exchange Commission, disclosing its Agreement and Plan of Merger with Pfizer Inc. and Aris Merger Sub, Inc.
• The merger is expected to be completed in late 2023 or early 2024, subject to regulatory approvals and other closing conditions.
• Seagen Inc. and Pfizer have filed a Notification and Report Form with the Federal Trade Commission and Department of Justice.
• The statutory waiting period under the HSR Act is set to expire on July 14, 2023.
• The merger agreement was first disclosed on March 12, 2023, and the initial filing was made on May 12, 2023.
• The parties have agreed to withdraw the initial filing and refile it, effective June 14, 2023.
• Seagen Inc. and Pfizer have referred the merger to the European Commission for review under Article 4(5) of the EU Merger Regulation.
• The merger is contingent upon receipt of approval from the European Commission, with the approval serving as a condition for closure.
• The acquisition remains subject to customary closing conditions, including receipt of required regulatory approvals.
• The Company continues to expect the merger to be completed in late 2023 or early 2024, subject to the fulfillment of customary closing conditions.
• Information set forth herein constitutes forward-looking statements, which are subject to material risks and uncertainties outside of the Company's control.

Statistics:

• The merger is expected to be completed in late 2023 or early 2024.
• The statutory waiting period under the HSR Act is set to expire on July 14, 2023.
• The initial filing was made on May 12, 2023.
• The merger agreement was first disclosed on March 12, 2023.
• Seagen Inc. has 91,187,439 shares of common stock outstanding.

Sources:

• UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023